Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2025-10-14 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
国泰海通证券股份有限公司关于上海宣泰医药科技股份有限公司差异化分红事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution regarding a differentiated dividend distribution related to a company's share repurchase and profit distribution plan. It discusses the specifics of the dividend distribution, share repurchase details, calculation of dividend amounts, and compliance with relevant laws and regulations. The document does not present itself as a full financial report or earnings release but rather as a regulatory or compliance opinion related to dividend distribution and share repurchase. It is not an announcement of voting results, nor a proxy statement, nor a management report. Given the nature of the content focusing on regulatory compliance and verification of dividend distribution details, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2025-10-14 Chinese
关于持股5%以上股东部分股份质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the pledge of shares by a shareholder holding more than 5% of the company's shares. It details the number of shares pledged, the proportion of total shares, and related information about the pledge. There is no indication of financial statements, management discussion, or other report content. The document is a regulatory announcement about share pledge by a major shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or earnings release.
2025-10-10 Chinese
国泰海通证券股份有限公司关于上海宣泰医药科技股份有限公司增加2025年度日常关联交易预计额度的核查意见
Regulatory Filings
2025-09-30 Chinese
关于公司高级管理人员离任的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management officer, specifically the vice general manager Wu Huafeng, including details about the resignation date, reasons, and impact on the company. It does not contain financial data, audit information, or any report content. It clearly fits the category of Board/Management Information (MANG) as it announces changes in senior management.
2025-09-30 Chinese
关于增加2025年度日常关联交易预计额度的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the increase in the estimated amount of daily related-party transactions for the year 2025 by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It details the nature of the transactions, the approval process by the board and independent directors, the related parties involved, and the rationale behind the increase. The document does not contain financial statements or detailed financial performance data but is a regulatory announcement about a specific corporate action related to related-party transactions. It is not an annual report, interim report, earnings release, or any other detailed financial report. It fits best under the category of Regulatory Filings (RNS) as it is a compliance disclosure about related-party transactions and their approval.
2025-09-30 Chinese
自愿披露关于西格列汀二甲双胍缓释片新增规格获得国家药品监督管理局批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the approval by the National Medical Products Administration (国家药品监督管理局) of a new specification for a drug product (Sitagliptin Metformin Sustained Release Tablets). It details the drug's basic information, approval details, and potential impact on the company. The document is short (1189 characters) and is an announcement of regulatory approval rather than a financial report or detailed corporate filing. It does not contain financial data, management changes, voting results, or other report types. It is a regulatory announcement about product approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-09-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.